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Classical swine fever virus (CSFV) is highly contagious, and fatal to infected
pigs. Vaccines against CSFV have been developed from attenuated or modified
live viruses. These vaccines are effective for immunization of animals, but they
are associated with problems such as the accidental spreading of viruses to
animals in the field, and with barriers to trade following vaccination. Here, we
report the generation of transgenic Nicotiana benthamiana plants for large-scale,
cost-effective production of E2 fusion protein for use as a recombinant vaccine
against CSFV in pigs. Transgenic N. benthamiana plants harboring an intergenic,
single-copy insertion of a chimeric gene encoding E2 fusion protein had high levels
of transgene expression. For large-scale production of E2 fusion protein from leaf
tissues, we developed a protein-purification protocol consisting of cellulose-binding
domain (CBD)–cellulose-based affinity purification and size-exclusion gel-filtration
chromatography. E2 fusion proteins showed high immunogenicity in piglets and
provided protection against CSFV challenge. The CBD in the E2 fusion protein was
also highly immunogenic. These results suggest that plant-produced recombinant E2
fusion proteins can be developed into cost-effective vaccines against CSFV, with the
CBD as a marker antigen to differentiate between vaccination and natural infection.
Keywords: Nicotiana benthamiana, classical swine fever (CSF), DIVA vaccines, molecular farming in plants,
plant-made vaccines
INTRODUCTION
Classical swine fever (CSF) is one of the most important viral diseases of domestic and wild pigs
(Edwards et al., 2000). CSF is highly contagious and produces high fever, depression, anorexia,
gastrointestinal symptoms, and conjunctivitis, leading to considerable mortality and substantial
economic losses (Laevens et al., 1999; Fritzemeier et al., 2000; Moennig et al., 2003). CSF is caused
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by classical swine fever virus (CSFV), which belongs to the genus
Pestivirus within the family Flaviviridae (Moennig, 2000). CSFV
is an RNA virus with a single-stranded, positive RNA genome
of approximately 12.3 kb that encodes a polypeptide of 3,898
amino acid residues (Rümenapf et al., 1993). This polypeptide
is processed to produce 12 proteins, comprising four structural
proteins (C, Erns, E1, and E2) and eight non-structural proteins
(Npro, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Meyers
et al., 1996). In addition, the genome contains a 5′ untranslated
region (UTR) and a 3′UTR.
CSF is widely prevalent in pig populations in Europe, Asia,
and South America (Greiser-Wilke et al., 2000; Tu et al., 2001;
Deng et al., 2005; Cha et al., 2007; Postel et al., 2013). Moreover,
the disease is endemic in some countries, including India, China,
and Korea (Cha et al., 2007; Luo et al., 2014; Roychoudhury
et al., 2014; Blome et al., 2017). Because of high mortality,
outbreaks of CSF can cause significant damage to the swine
industry (Saatkamp et al., 2000; Stegeman et al., 2000). CSF is
therefore classified as a List A disease by the Oficina Internacional
de Epizootias (OIE) (Edwards et al., 2000; OIE, 2013). To control
the disease, vaccines derived from live, attenuated virus or the
E2 subunit are commercially available (Paton et al., 2000; Deng
et al., 2005; Blome et al., 2006; Suradhat et al., 2007). Vaccination
with live, attenuated virus has been used in eradication programs
throughout the world, and is still being used in endemically
affected countries. However, in CSFV-free countries, prophylactic
vaccination is usually prohibited. In this context, marker vaccines
that can differentiate vaccinated animals from naturally infected
animals are preferred, as they can reduce adverse impacts on
trade (Blome et al., 2013).
There have been various attempts to develop marker vaccines
for CSFV (Weiland et al., 1990; König et al., 1995). E2
protein, one of the coat proteins of CSFV, was identified as
an antigen that can provide protective immunity, and has
been used for the development of subunit vaccines (Depner
et al., 2001; Uttenthal et al., 2001). The subunit vaccines can
be safer than vaccines produced from attenuated live virus
or modified live virus (Dong and Chen, 2007). E2 proteins
produced in insect cells have been used as vaccines for pigs
(Galliher-Beckley et al., 2015; Madera et al., 2016). In addition,
E2 proteins produced in Arabidopsis thaliana are recognized
by antibodies raised against native E2 proteins, and elicit
production in mice of antibodies that recognize native E2
proteins (Sohn et al., 2018), suggesting that plant-produced
proteins can be used as vaccines in target animals. Moreover,
E2 proteins expressed transiently in Nicotiana benthamiana
following transformation with Agrobacterium tumefaciens elicit
production of CSFV-neutralizing antibodies in pigs and give
protection from challenge with CSFV (Laughlin et al., 2018).
In this study, we investigated whether recombinant E2
fusion protein could be expressed at high levels in transgenic
N. benthamiana plants by intergenic insertion of a single-copy
transgene, and whether expressed fusion protein could be
purified in a cost-effective manner for commercialization.
Our results indicate that the E2 fusion protein is strongly
immunogenic, protecting pigs against CSFV challenge. The
recombinant E2 fusion protein was expressed at a high level, and
purified at a low cost. Furthermore, the cellulose-binding domain
(CBD) region of the fusion protein is highly immunogenic
and can be used as a marker for animals vaccinated with the
recombinant E2 fusion protein.
RESULTS
Construction of an E2 Expression Vector
and Protein Expression in Leaves of
Transgenic N. benthamiana
To test the potential of recombinant E2 fusion protein for use
as a vaccine, preparation of a large amount of the protein was
necessary. N. benthamiana was assessed for protein production,
because transgenic A. thaliana plants had previously been
found to have a limitation for production of biomass (Sohn
et al., 2018). Notably, N. benthamiana has been used as a
host for production of many different recombinant proteins
(Holtz et al., 2015). We previously demonstrated that a fusion
construct containing the E2 gene of CSFV results in a high
level of protein expression in the endoplasmic reticulum (ER)
of transgenic A. thaliana (Sohn et al., 2018). Accordingly, in
this study, a similar construct with only minor differences was
used (Figure 1A). The chimeric construct included BiP signal
peptide and HDEL ER-retention signal, for accumulation of
the fusion protein in the ER. A CBD was included as an
affinity tag to facilitate purification. The tobacco etch virus
(TEV) protease site was inserted between the E2 and CBD
sequences, to enable removal of the CBD. The construct
therefore directs expression of a BiP:E2:TEV:CBD:HDEL fusion
protein. A 17 bp 5′ UTR (M17) that has demonstrated high
translational efficiency (Kim et al., 2014) was also included.
The final M17:BiP:E2:TEV:CBD:HDEL construct was named
MELCHE2. The cauliflower mosaic virus (CaMV) 35S promoter
and A. tumefaciens nopaline synthase gene (nos) terminator were
used for expression of the chimeric construct.
The MELCHE2 construct was inserted into the
pCAMBIA1300 binary vector to give 1300::MELCHE2, which
was introduced into A. tumefaciens and used for generation of
transgenic N. benthamiana plants. Many putative transgenic
plants (T0 plants) were obtained and examined for expression of
plant-produced E2 fusion protein (ppE2) by western-blot analysis
using anti-CBD antibody (Figures 1B,C). Extracts from most
of these T0 plants produced a band at 66 kD, in contrast to the
expected 58 kD of the E2 fusion protein (39 kD of E2 and 19 kD
of other domains including CBD). One possible explanation
for this discrepancy is that the ppE2 was N-glycosylated in
N. benthamiana, as has been observed in A. thaliana. Notably, E2
protein has multiple N-glycosylation sites (Risatti et al., 2007).
According to a glycosylation analysis algorithm1, E2 protein
contains six putative N-linked glycosylation sites. The expression
level of ppE2 varied considerably among the 16 transgenic
plants that were screened, with transgenic line number 18
showing the highest expression. This line was therefore used in
further experiments.
1http://www.cbs.dtu.dk/services/NetNGlyc/
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FIGURE 1 | Design of the MELCHE2 construct and selection of transgenic plants expressing recombinant E2 fusion protein at high levels. (A) Schematic view of the
MELCHE2 construct. 35S, double cauliflower mosaic virus 35S promoter; M17, 5′ untranslated region; BiP, endoplasmic reticulum (ER)-targeting signal peptide; E2,
classical swine fever virus envelope glycoprotein E2; TEV, tobacco etch virus protease site; CBD, cellulose-binding domain of xynA; HDEL, ER-retention signal;
tNOS, nos terminator. (B,C) Western-blot analysis of recombinant E2 fusion proteins expressed in T0 transgenic plants. Total protein was prepared from 16
independent lines at T0, and 50 µg of each extract was subjected to western blotting using anti-CBD antibody. Blots were stained with Coomassie Brilliant Blue after
immunoblotting, as shown in the lower panel. M, protein standards (molecular weights in kD shown to the left); P, CBD positive control (GFP:CBD 10 ng); W,
wild-type Nicotiana benthamiana used as a negative control.
Molecular Characterization of
Transgenic Plants Expressing ppE2
We characterized transgenic line number 18. According to
the guidelines for biosafety of genetically modified plants in
South Korea2, a single copy of the transgene should be inserted
in an intergenic region. We tested the copy number of the
T-DNA by assessing hygromycin resistance. On hygromycin
plates, T2 plants segregated with a 1:3 ratio of sensitive to
resistant plants, indicating that transgenic line 18 has a single
insertion of the T-DNA. We also determined the exact copy
number of the transgene in line 18–10, one of the T3 homozygotic
lines derived from transgenic line 18. First, we used PCR to
detect the hygromycin antibiotic-resistance gene that is used
for selection of transgenic plants, as well as the CaMV 35S
2http://www.nih.go.kr
promoter and E2:TEV:CBD regions of the MELCHE2 construct.
Total genomic DNAs from line 18–10 and from wild-type plants
were prepared and used as templates for gene-specific PCR.
The products were analyzed by gel electrophoresis. PCR with
template DNA from transgenic line 18–10 produced specific
bands for each of these targets, whereas template DNA from
wild-type plants did not yield any bands (Figure 2A), indicating
that transgenic line 18–10 contains the transgene as well as
the drug-resistance gene. To determine the copy number, we
performed Southern-blot analysis using genomic DNA from T2,
T3, and T4 plants of transgenic line 18–10 and from wild-type
plants. This DNA was digested with restriction endonuclease
BamH1, EcoR1, or XbaI, and separated on agarose gels. DNA
digested with BamH1 or XbaI was probed with a DNA fragment
from the E2:TEV:CBD region, and DNA digested with EcoR1
was probed with a fragment from hygromycin resistance gene.
For T2, T3, and T4 plants of transgenic line 18–10, each of
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these restriction-endonuclease treatments produced only a single
band (Figure 2B), indicating that the transgene and hygromycin
resistance gene are present as single copies in the host genome.
No bands were observed following digestion of genomic DNA
from wild-type plants.
To determine the exact point of insertion of the MELCHE2
construct, we isolated the ends of the construct together
with the neighboring genomic DNA by inverse PCR (iPCR)
(Figure 2C). Genomic DNA was fragmented by treatment
with BamH1, which has a restriction site near to the BiP
signal peptide, or with EcoR1, which has a site near to the nos
terminator. DNA fragments produced by restriction digestion
were self-ligated to produce circular DNA molecules, which were
used as templates for iPCR. Amplified products between 0.8 and
1.5 kb were isolated, inserted into T-vector (Solgent; Cat No.
SOT02-K020), and sequenced. The sequences were compared
with the full genome sequence from the Sol Genomics Network
database3, which showed that the genomic regions adjacent
to right border (RB) and left border (LB) matched sequences
in the N. benthamiana contigs Niben101Scf08318Ctg002
and Niben101Scf08318Ctg003, respectively (Supplementary
Figure S1). A further sequence-similarity search was performed
with the Basic Local Alignment Search Tool (BLAST)4, and
the genomic DNA sequence around MELCHE2 corresponded
to the non-coding region upstream of the WAT1-related gene
in Nicotiana tomentosiformis, indicating that the MELCHE2
construct is inserted in an intergenic region. To further confirm
this, we designed primers flanking the predicted insertion site
and amplified the genomic DNA by PCR. When annealing
temperature was 63◦C, a DNA fragment containing T-DNA and
genomic DNA region of approximately 7 kb was produced from
the transgenic plants harboring the MELCHE2 construct, but no
bands were produced by PCR with template DNA from wild-type
plants at an expected size (Figure 2D). As annealing temperature
was lowered, the band composed of only genomic DNA region
was observed from wild-type plants although multiple bands
including a specific target band were detected in the transgenic
plants. Taken together, these results suggest that a single copy of
the fusion construct is inserted into an intergenic region.
Purification and N-Terminal Sequencing
of ppE2
To obtain plant-produced CSFV E2 antigen, extracts were
prepared from 1 g of T3 plants of transgenic line 18–10 and used
for purification of ppE2 by our previously established CBD-based
affinity method (Sohn et al., 2018), with analysis of fractions by
western blotting with anti-CBD antibody (Figure 3A). Following
the application of total protein extract to the amorphous cellulose
beads, the flow-through contained around 30% of unbound ppE2,
compared to that of total extracts. The three wash fractions
produced only faint bands at 66 kD on western blots, indicating
that ppE2 binds tightly to the cellulose beads. The two elution
fractions obtained by application of 1% cellobiose produced
intense bands at 66 kD. After elution, little further protein
3https://solgenomics.net
4https://blast.ncbi.nlm.nih.gov/Blast.cgi
was released by boiling the cellulose beads. Electrophoresis
and protein staining demonstrated that the majority of cellular
proteins were present in the unbound flow-through fraction
(Figure 3A). A strong band at 55 kD, indicative of the large
subunit of the rubisco complex, was observed in the first
wash fraction, whereas no clear protein bands were observed
in the other two wash fractions. The only visible protein
bands in the two elution fractions corresponded to ppE2,
indicating that it can be purified to near homogeneity by
CBD-based affinity purification, as shown previously for extracts
of transgenic A. thaliana harboring a similar construct to
MELCHE2 (Sohn et al., 2018).
Eluted protein fractions were concentrated 10-fold by
centrifugal filtration, and aliquots were run alongside known
amounts of bovine serum albumin (Figure 3B). By comparison
of the intensities of protein staining, we estimated that the ppE2
concentration was 228 µg/ml, and that 16 µg of ppE2 could be
obtained from 1 g fresh weight of plant leaves.
Electrophoresis of denatured purified ppE2 demonstrated the
presence of a major band at 66 kD and a minor band at>180 kD,
which suggested that ppE2 could form a high-molecular-weight
complex. Notably, E2 proteins have previously been shown
to form dimers (Lin et al., 2009; Hua et al., 2014). With
size-exclusion gel-filtration chromatography, we found that
purified ppE2 produced two peaks, at 45 and 55 ml elution
volumes (Figure 3C). The 45 ml peak eluted earlier than a 440 kD
marker protein. In non-denaturing electrophoresis, proteins
from the 45 ml peak did not produce a band on the gel. These
proteins may be aggregated forms of ppE2 that are too large
to enter the gel. By contrast, the proteins from the 55 ml peak
produced a band at ∼230 kD, suggesting that these proteins are
multimers of ppE2. The occurrence of multimers larger than
dimers might result from the presence of the additional domains
in the E2 fusion protein.
Next, we examined the N-terminus of ppE2. The MELCHE2
construct encoded a BiP signal peptide that should be removed
after targeting to the ER, but the exact cleavage site is not known.
We determined the N-terminal amino acid residue of the purified
ppE2 by Edman degradation in an automated manner. Amino
acid sequence analysis showed that the BiP signal peptide was
cleaved between Ala27 and Ile28, resulting in 10 amino acids
overhang at the N-terminus of ppE2 fusion protein (Figure 3D).
ppE2 Generated in N. benthamiana
Induces Production of
CSFV-Recognizing Antibody in Piglets
We assessed recognition of recombinant E2 fusion protein
generated in N. benthamiana (0.25–64 ng/µl) by a commercially
available E2-directed anti-CSFV ELISA (Figure 4). At 0.25 ng/µl,
the recombinant protein signal was similar to that of the
antigen provided as a weak positive control in the ELISA kit.
The signal intensity increased with increasing concentrations of
recombinant protein, and at>1 ng/µl it was stronger than that of
the strong positive control.
We examined whether ppE2 generated in N. benthamiana
could induce production of anti-E2 antibody in pigs. E2 fusion
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FIGURE 2 | Transgenic plant line 18–10 contains only a single-copy insertion of the MELCHE2 construct in an intergenic region. (A) PCR analysis of the T-DNA in
transgenic Nicotiana benthamiana line 18–10. Genomic DNA was extracted and used for PCR amplification of hygromycin resistance gene, 35S promoter, and
E2:TEV:CBD:HDEL. PCR products were analyzed by agarose-gel electrophoresis. M, DNA size markers (relevant sizes indicated to the left of
the panel); WT, wild type. (B) Southern-blot analysis of transgenic line 18–10. Genomic DNA from T2, T3, and T4 generations of line 18–10 was digested with restriction
(Continued)
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FIGURE 2 | Continued
endonuclease BamHI, EcoRI, or XbaI, and probed with E2:TEV:CBD:HDEL-specific or hygromycin resistance gene-specific probes (hygromycin resistance gene). M,
DNA size markers (relevant sizes indicated to the left of the panel); WT, wild type. (C) Schematic view of the fusion construct T-DNA, restriction sites of BamHI, XbaI
and EcoRI and primer sets used for iPCR. XbaI, upstream of BiP and BamHI, downstream of BiP were used for finding out RB insertion site. EcoRI, downstream of
tNOS was used for LB insertion site. (D) Isolation of the full-length T-DNA in transgenic line 18–10 by PCR. The primer set was designed from the genomic DNA
regions around the LB and RB insertion sites, as indicated in (C). PCR was performed with genomic DNA of wild-type plants and transgenic line 18–10 as template.
Two independent reactions were carried out at different annealing temperature 63oC (left panel) or 58oC (right panel), respectively. PCR products were analyzed by
agarose-gel electrophoresis. M, DNA size markers (relevant sizes indicated to the left of the panel); WT, wild type.
protein (50 or 100 µg) was mixed with the adjuvant IMS1313 and
subcutaneously injected into piglets (Figures 5A,B). Each group
included two animals. Before immunization, preimmune control
serum was obtained from each animal. Neither experimental
group had detectable levels of CSFV-recognizing antibodies at the
time of the first injection, but these antibodies were detectable at
the time of the second injection, and titers increased considerably
thereafter, reaching maximal levels 7 days after the second
injection (Figure 5C). No CSFV-recognizing antibodies were
detected in control animals that were not immunized.
With the live CSFV vaccine that is currently used in
Korea, vaccinated animals cannot be distinguished from
naturally infected animals. We examined whether the presence
of C-terminal CBD results in the production of anti-CBD
antibodies that can function as markers for vaccination by
ppE2 (Figure 5D). For an anti-CBD-specific ELISA, serum from
immunized pigs was diluted 1,000- or 2,000-fold and incubated
with 15 ng of CBD. No difference was observed between the
ELISA signal intensities for serum samples from pigs vaccinated
with 50 or 100 µg of ppE2. However, serum from animals
vaccinated with the live CSFV strain LOM did not produce a
signal in the anti-CBD ELISA. These results indicate that the CBD
is an effective antigen that can be used as a marker to distinguish
animals vaccinated with ppE2 from animals vaccinated with live
virus or naturally infected in the field.
ppE2 Produced in N. benthamiana
Provides Protection Against CSFV in
Piglets
To test whether ppE2 can provide protection against CSFV
in target animals, we performed viral-challenge experiments.
Piglets vaccinated with two doses of 50 or 100 µg of ppE2 were
challenged with a virulent strain of CSFV (YC11WB) 2 weeks
after the second vaccination, and clinical symptoms such as high
fever and reduction in white blood cells (WBCs) were monitored
after viral challenge. Regardless of the vaccination dose, all
vaccinated piglets showed a normal range of body temperature
(38–40◦C) during monitoring for 13 days post-challenge (DPC)
(Figure 6A). When WBCs were counted, Numbers of WBCs
fluctuated, but remained above 9,000 cells per mm3, which is
considered the lower limit of normal WBC levels (Figure 6B).
To assess viremia following the viral challenge, total RNA was
prepared from the serum of vaccinated pigs at different time
points and subjected to one-step RT-PCR using CSFV-specific
primers to detect the 5′ non-coding region (5′ NCR) of CSFV
(Table 1). In pigs vaccinated with 50 µg of ppE2, a positive
reaction was observed only on day 7 post-challenge. No positive
reactions were observed with a vaccination dose of 100 µg of
ppE2. This result suggests that a higher vaccination dose might
be more effective for protection of pigs from CSFV.
The presence of CSFV in the tissues of vaccinated animals
following viral challenge was also assessed (Table 2). Total RNA
was prepared from the tissues and analyzed by one-step RT-PCR
using CSFV-specific primers. Tonsils from all piglets showed a
positive reaction, indicating the presence of CSFV, whereas no
CSFV RNA was detected in the other tissues.
Single-Dose Vaccination With ppE2
Effectively Protects Pigs Against Virulent
CSFV
When animals are vaccinated, it is desirable to reduce the
number of required injections. We examined whether single-
dose vaccination with ppE2 can give long-lasting protection.
Animals were injected once with ppE2 (100 µg) and then
challenged with YC11WB strain. For a positive control, animals
were vaccinated once with the LOM CSFV strain. Viral challenge
was carried out at different times after vaccination of 10 weeks old
piglets (four per group) (Figure 7A). All piglets were monitored
for 21 days unless they were euthanized. Unvaccinated piglets
and piglets with viral challenge 7 days post-vaccination all
died after displaying symptoms such as leucopenia and high
fever (Figures 7B–D). By contrast, piglets vaccinated with ppE2
and challenged 11 or 14 days post-vaccination, and piglets
vaccinated with LOM and challenged 14 days post-vaccination,
survived the CSFV challenge, although several showed temporary
leucopenia and high fever. CSFV-neutralizing antibody titers
were highest in piglets with viral challenge 14 days after ppE2
vaccination (Table 3), and titers in piglets with viral challenge
11 days after ppE2 vaccination were similar to those in piglets
with viral challenge 14 days after LOM vaccination, indicating
that ppE2 can provide full protection to animals from 11
days post-vaccination. These results suggest that single-dose
vaccination with ppE2 effectively protects pigs against virulent
CSFV challenge from 11 days post-vaccination, and maintains
high levels of antibody titers up to at least 21 DPC.
DISCUSSION
To date, modified live vaccine has been used for protection of
pigs against CSFV infection (Van Oirschot, 2003; Blome et al.,
2006). However, modified live viruses are immunologically
indistinguishable from wild-type CSFV in the field, highlighting
the importance of developing vaccines for differentiation of
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FIGURE 3 | Purification and identity confirmation of recombinant E2 fusion protein. (A) Purification of plant-produced E2 fusion protein (ppE2). Protein extracts
prepared from fresh leaves of transgenic Nicotiana benthamiana (1 g leaves/5 ml extraction buffer) were loaded onto a column containing 0.2 g of cellulose beads.
The column was washed three times, and wash-off fractions were collected. Proteins were eluted with 2 × 5 ml of elution buffer. Aliquots of total protein
(T), unbound fraction (Ub), wash-off fractions (W1–W3), and elution fractions (E1 and E2), as well as the post-elution cellulose-bead contents, were analyzed by western
(Continued)
Frontiers in Plant Science | www.frontiersin.org 7 May 2019 | Volume 10 | Article 624
fpls-10-00624 May 15, 2019 Time: 16:33 # 8
Park et al. ppE2 Protects Against CSFV Virus
FIGURE 3 | Continued
blotting using anti-CBD antibody. (B) Quantification of purified ppE2. Purified ppE2 was concentrated using 50 kD-cutoff centrifugal concentrators and analyzed by
SDS-PAGE. Proteins were visualized by Coomassie Brilliant Blue staining. Bovine serum albumin (BSA) was used for comparison. (C) Size-exclusion
chromatography and native-PAGE analysis of ppE2. Purified ppE2 was injected onto the equilibrated column and separated, with collection of 1.5 ml fractions.
Fractions corresponding to absorbance peaks (marked with a green circle and a red box) were analyzed by 9% native PAGE and stained with Coomassie Brilliant
Blue. Ferritin (440 kD), aldolase (158 kD), and conalbumin (75 kD) were used as molecular-weight standards. (D) Amino acid sequencing of ppE2 fusion protein.
ppE2 (0.4 mg/ml) in PBS buffer containing cellobiose was subjected to Edman degradation in an automated manner. Amino acid residues in red indicate BiP
residues of ppE2 following cleavage during endoplasmic reticulum targeting. Putative N-linked glycosylation sites are shown in bold.
FIGURE 4 | E2 fusion protein produced in Nicotiana benthamiana is recognized by an antibody to E2 of classical swine fever virus. (A) Quantification of the reactivity
of plant-produced E2 fusion protein (ppE2) with anti-E2 antibody. Purified ppE2 was serially diluted and analyzed by ELISA, along with a strong protein control (SPC)
and a weak protein control (WPC), with measurement of signal intensity at A450. (B) Visualization of the reactivity of ppE2 with anti-CSFV E2 antibody. Purified ppE2
was added to wells of an anti-CSFV E2 antibody-coated plate, and the reactivity was visualized using 3,3′,5,5′-Tetramethylbenzidine as substrate. Lanes 1–9,
purified ppE2; SPC, strong positive control; WPC, weak positive control; NC negative control.
infected from vaccinated animals. Plants are good bioreactors
for vaccine production, because they produce clinical-grade
materials quickly and are easily scalable for large-scale
production (Holtz et al., 2015; Nandi et al., 2016). Therefore,
we generated a recombinant construct containing E2 of CSFV,
expressed the recombinant E2 fusion protein in transgenic
plants, and examined whether ppE2 could provide protection
against virulent CSFV.
In general, transient expression has been shown to give
higher levels of protein expression in plants than the
transgenic approach (Yamamoto et al., 2018). Therefore,
transient expression is typically favored when aiming for
high yield in relation to biomass. Transient expression
also does not require the lengthy screening process that is
necessary to obtain a transgenic plant expressing the target
gene at high levels (Garabagi et al., 2012). However, the
transgenic approach also has some advantages, including
avoidance of concerns relating to endotoxins that occur with
the use of A. tumefaciens for transformation. In addition,
because upstream processes such as agroinfiltration involving
additional equipment and materials can be eliminated once the
homozygous transgenic lines were generated, the transgenic
approach is less laborious and is more cost-effective for protein
production (Garabagi et al., 2012). Another advantage of the
transgenic approach is its scalability once the expression
line has been established. In this study, we selected a
transgenic line with high expression of the recombinant
E2 fusion protein, and determined that this expression
was directed by a single copy of MELCHE2 inserted in an
intergenic region.
For economical large-scale production of recombinant
proteins, it is essential that the costs associated with protein
purification should be minimized. Our strategy was to use
CBD for the purification of the fusion protein. Cellulose is
an inexpensive and readily available biomaterial that can be
used as a matrix for affinity-based protein purification, and
the CBD has high affinity to amorphous cellulose (Wan et al.,
2011; Sugimoto et al., 2012; Armenta et al., 2017). Thus,
CBD–cellulose binding is the basis of a cost-effective method
for protein purification. Previously, we successfully used this
approach to purify a similar recombinant E2 fusion protein
from A. thaliana (Sohn et al., 2018). Here, this method enabled
purification of ppE2 from extracts of N. benthamiana. Although
E2 proteins naturally exist as dimers, our results suggested that
ppE2 occurred as a multimer.
In the development of vaccines from plant-produced
recombinant proteins, the most important target variable is
immunogenicity. The ppE2 generated from N. benthamiana was
recognized in a commercially available ELISA by an antibody
directed against CSFV E2 protein. In addition, a protocol of
priming and boost injections of piglets with 50 or 100 µg
of ppE2 produced anti-E2 antibodies and provided effective
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FIGURE 5 | ppE2 is highly immunogenic and induces production of antibody against E2 in piglets. (A) Schematic presentation of the two-dose immunization
protocol. DPV, days post-vaccination. Blood was collected immediately before injection and at the indicated DPV. (B) Immunization of piglets. The piglets were
injected twice with 50 µg or 100 µg of plant-produced E2 fusion protein (ppE2) in 50% IMS1313 used as an adjuvant. For each dose, three piglets were immunized.
(C) E2-specific immune response, determined by ELISA. Serum samples collected from piglets vaccinated with ppE2 were analyzed for E2-specific immune
responses by ELISA. Non-vaccinated piglets were included as negative control. Data are mean ± SEM for three pigs per group. (D) Cellulose-binding domain
(CBD)-specific immune response, determined by ELISA. Serum samples collected from piglets vaccinated with ppE2 or LOM live vaccine were diluted by 1:1,000 or
1:2,000 and used to analyze CBD-specific immune responses by ELISA. Data are mean ± SEM for three pigs per group.
FIGURE 6 | Plant-produced E2 fusion protein vaccination provides protection from classical swine fever virus challenge. (A,B) Two piglets were immunized with two
doses of either 50 µg or 100 µg of plant-produced E2 fusion protein (ppE2), and challenged with virulent classical swine fever virus (CSFV). Symptoms of CSFV
infection in vaccinated animals are shown. Body temperature (A) and total leukocyte counts (B) were examined at 0, 3, 5, 7, 10, and 13 days after viral challenge.
The individual data points were presented.
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TABLE 1 | Detection of viremia in serum from vaccinated piglets challenged with classical swine fever virus.
Group Viremia rates at the day post challenge
0 DPC 3 DPC 5 DPC 7 DPC 10 DPC 13 DPC
ppE2-50 1 – – – + – –
2 – – – + – –
No. of (+) reaction/ Total 0/2 0/2 0/2 2/2 0/2 0/2
ppE2-100 1 – – – – – –
2 – – – – – –
No. of (+) reaction/ Total 0/2 0/2 0/2 0/2 0/2 0/2
(−); undetectable; viremia rates at each day post-challenge (DPC) was detected by RT-PCR as described in Materials and Methods section.
TABLE 2 | Detection of CSFV RNA in several tissues after challenge.
Group The presence of CSFV at the animal tissues
Tonsils Heart Liver Lung Kidney Spleen Mesenterv Ileum Caecum Brain
ppE2-50 1 + – – – – – – – – –
2 + – – – – – – – – –
No. of (+) reaction /Total 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
ppE2-100 1 + – – – – – – – – –
2 + – – – – – – – – –
No. of (+) reaction /Total 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0’2
(−); undetectable; RNA was extracted from each tissue, and CSFV was detected by RT-PCR as described in Materials and Methods section.
protection against virulent CSFV challenge. The vaccinated
piglets did not display severe clinical symptoms such as viremia,
high fever, and leucopenia, suggesting the possibility of using
ppE2 as a vaccine against CSFV. However, there was no clear
correlation between the amount of E2 injected into animals and
antibody titers or a few symptoms after virus challenge. One
possible explanation is that this may be due to the condition
of each pig. In the viral challenge experiments, the number
of pigs in each group was only two, thereby leading to high
data variations. Thus, the data were not suitable for statistical
analysis. Thus, these results require cautious interpretation and
experiments should be repeated with a sufficient number of
piglets in the future study. Nevertheless, single-dose vaccination
provided effective protection against CSFV challenge, which
was comparable to that of the LOM vaccine that is currently
used in the field in Korea, further supporting the potential
of ppE2 as a subunit vaccine against CSFV in pigs. These
results are consistent with previous findings that single-dose
vaccinations with E2 produced in insect or plant expression
systems effectively protect pigs against CSFV infection (Galliher-
Beckley et al., 2015; Madera et al., 2016; Laughlin et al., 2018).
Here, we found that a single-dose ppE2 vaccination with 100 µg
requires 11 days to give full protection from CSFV infection,
similar with commercial E2 subunit vaccines which give full
protection at 14 days post-vaccination but partial protection
before 10 days post-vaccination (Bouma et al., 2000; Uttenthal
et al., 2001). This result proposes that not only MLV vaccine
but also E2 subunit vaccine can be useful in an emergency
situation. However, a new immunization protocol is needed for
the early onset of protection. To obtain protection at earlier
time points, one possible solution is to use greater amounts
of ppE2 for vaccination. In fact, we used 100 µg of ppE2 for
single-dose vaccination, whereas Laughlin et al. (2018) used
200 µg of E2. We also noticed the difference in the protein
composition; ppE2 protein fused with CBD in this study existed
as multimer whereas E2 protein of Laughlin et al. (2018)
had the native structure, dimer, raising the possibility that
the difference in the E2 protein composition may affect the
antigenicity. The effectiveness of such a strategy could be tested
in future research.
CONCLUSION
In conclusion, we successfully generated transgenic
N. benthamiana plants with single-copy insertion of the
MELCHE2 construct in an intergenic region. These plants
produced recombinant E2 fusion protein, enabling us to purify
the protein from extracts of N. benthamiana leaf tissues to high
purity. We demonstrated the antigenicity and immunogenicity
of ppE2, which provided effective protection against CSFV
infection following priming and boost injections of piglets. We
also demonstrated the possibility of single-dose vaccination
with 100 µg of ppE2, with the caveat that at least 11 days were
required for the development of protection.
MATERIALS AND METHODS
Plant Growth Conditions
N. benthamiana plants were grown on soil composed of zeolite
(30 g), pearlite (130 g), coco-peat (705.3 g), peat moss (130 g) and
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FIGURE 7 | Single-dose vaccination with plant-produced E2 fusion protein can provide effective protection after 11 days. (A) Schedules of single-dose vaccination
and challenge with virulent classical swine fever virus (CSFV). Piglets were vaccinated with plant-produced E2 fusion protein (ppE2) or live CSFV vaccine strain LOM.
Survival and clinical conditions of vaccinated pigs after viral challenge were monitored at 0, 3, 7, 10, 14, 17, and 21 days post-challenge. (B) Survival of immunized
and control (non-immunized) piglets. (C,D) Symptoms of CSFV infection in animals with single-dose vaccination. Body temperatures (C) and the number of WBCs
(D) from all piglets were examined at the indicated time points until the animals died or were euthanized. Piglets from group 3 displayed abnormal clinical signs
before death, and non-vaccinated pigs all died soon after challenge. Data are mean ± SEM for four piglets per group.
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TABLE 3 | Single-dose vaccination and classical swine fever virus (CSFV)-neutralizing antibody titers before and after viral challenge.
Group Pig# Before
vac-cination
3 DPV 7 DPV 10 DPV 14 DPV 3 DPC 7 DPC 10 DPC 14 DPC 17 DPC 21 DPC
G1 51 <4 <4 <4 4 32 64 128 2048 2048 1024 4096
52 8 8 8 8 32 32 256 2048 4096 2048 4096
53 4 4 <4 16 64 256 1024 2048 4096 2048 2048
54 <4 <4 <4 8 8 32 512 2048 2048 1024 2048
Group Pig# before
vac-cination
4 DPV 7 DPV 11 DPV 3 DPC 7 DPC 10 DPC 14 DPC 17 DPC 21 DPC
G2 55 4 16 4 32 32 64 128 512 512 1024
56 4 8 16 32 16 128 512 1024 2048 1024
57 4 <4 8 4 4 64 512 256 1024 2048
58 <4 8 16 16 16 64 1024 1024 1024 1024
Group Pig# before
vac-cination
3 DPV 7 DPV 3 DPC 7 DPC 10 DPC 14 DPC 17 DPC 21 DPC
G3 59 <4 <4 <4 4 4 <4 8 16 NA
60 <4 <4 <4 4 4 4 8 16 NA
61 <4 <4 <4 8 16 32 32 32 NA
62 <4 <4 <4 16 8 16 16 NA NA
Group Pig# before
vac-cination
3 DPV 7 DPV 10 DPV 14 DPV 3 DPC 7 DPC 10 DPC 14 DPC 17 DPC 21 DPC
G4 63 8 16 16 8 32 64 64 256 1024 1024 1024
64 8 4 8 16 32 128 256 256 1024 1024 1024
65 <4 <4 8 32 32 128 128 128 512 512 512
66 4 <4 16 32 128 128 128 256 512 512 512
Group Pig# before
vac-cination
3 DPV 7 DPV 10 DPV 14 DPV 3 DPC 7 DPC 10 DPC 14 DPC 17 DPC 21 DPC
G5 8 8 4 4 4 4 <4 NA NA NA NA
<4 <4 <4 <4 <4 <4 <4 NA NA NA NA
<4 <4 <4 <4 <4 <4 <4 NA NA NA NA
<4 <4 <4 <4 <4 <4 <4 NA NA NA NA
DPC, days post-challenge; DPV, day post-vaccination; NA, not available. CSFV-neutralizing antibody titers were measured as described in the Materials and Methods
section.
wetting agent (0.1 g), and heat-treated at 80◦C for 8 h before use.
The culture room was maintained 25◦C ± 2◦C and 50% ± 5%
relative humidity under a 16:8 h light:dark cycle. The light source
was LED lamp and intensity was 150 µmol·m−2·s−1.
Plasmid Construction and Generation of
Transgenic Plants
We used transmembrane domain deleted E2 derived from
LOM strain, which is commercially used in South Korea
as a modified live vaccine. To generate the MELCHE2
construct, a translation-enhancing sequence (M17; 5′-GG
CGTGTGTGTGTGTTAAAGA-3′) was added as the 5′ UTR
upstream of BiP signal peptide by use of the M17/BiP-F
forward primer, which contains both the M17 sequence
and 20 nucleotides (nt) of BiP1 (nucleotide positions 1–
20) (Kim et al., 2014). The reverse primer consisted of
6 nt of the BamHI restriction site and 21 nt of BiP1
(nucleotide positions 252–272) (Supplementary Table S1). The
E2 coding sequence was codon-optimized for expression in
N. benthamiana (Bioneer corp., Daejeon, Korea) and amplified
by PCR using primers E2-F and E2-R (Supplementary Table
S1). E2-F contained 6 nt of the BamHI restriction site and
22 nt of the E2 coding sequence (nucleotide positions 1–
22), and E2-R consisted of 6 nt of the XmaI restriction site
and 21 nt of the E2 coding sequence (nucleotide positions
1,002–1,023). The TEV:CBD:HDEL fragment was generated by
PCR. The forward primer consisted of 29 nt of a linker
sequence, 21 nt of the TEV protease site, and 20 nt of
Clostridium stercorarium xynA (nucleotide positions 1,554–
1,574), and the reverse primer contained 20 nt of xynA
(nucleotide positions 1,954–1,974) and 12 nt of HDEL (His-
Asp-Glu-Leu), which includes 6 nt of the SacI restriction site.
The resulting PCR products were digested with restriction
endonucleases BamHI and XmaI and ligated into, similarly,
digested pCAMBIA1300 binary vector, to generate 1300MELCH.
To generate transgenic plants expressing MELCHE2 encoding
the E2 fusion protein, 1300MELCH was introduced into
A. tumefaciens strain LBA4404, following a previously described
method (Horsch et al., 1985). N. benthamiana leaves were cut
into 0.5 cm × 0.5 cm pieces and incubated in Murashige and
Skoog (MS) medium containing 2.0 mg/l α-naphthaleneacetic
acid (NAA), 0.5 mg/l 6-benzylaminopurin (6-BAP), and 100 µl
of a culture of A. tumefaciens transformed with 1300MELCH,
for 10 min. The solution was removed by blotting with
sterilized filter paper. Leaf segments were placed upside
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down on MS-agar plates containing 1.0 mg/l NAA and
0.5 mg/l 6-BAP, and incubated for 3 days. They were then
washed with 10 ml of MS containing 1.0 mg/l NAA and
0.5 mg/l 6-BAP, which was removed with sterilized filter paper.
Leaf segments were then placed upside down on MS-agar
plates containing 1.0 mg/l NAA, 0.5 mg/l 6-BAP, 200 mg/l
kanamycin, and 250 mg/l cefotaxime, and incubated in the
dark for 7–10 days. Leaf segments were then transferred
to the light to induce shoot and root formation, on MS-
agar plates containing 200 mg/l kanamycin and 250 mg/l
cefotaxime. Transformed plants were transferred to soil, and
expression of the E2 fusion protein was analyzed by western
blotting. Seeds were harvested from transgenic plants with
high expression, and homozygous plants were selected at
T3 generation based on the 3:1 segregation ratio in the
presence of antibiotics.
Protein Purification and Western Blotting
Leaf tissues from transgenic plants were harvested and ground
in liquid nitrogen. Total protein extracts were prepared in five
volumes of protein-extraction buffer (50 mM NaOAc, pH 5.2,
50 mM NaCl, 1 mM CaCl2, 0.1% Triton X-100) and incubated
on ice for 30 min. Homogenates were centrifuged at 20,000 × g
for 30 min, and supernatants were collected. Total protein
extract (5 ml) was loaded onto a column containing 0.2 g
of amorphous cellulose beads (Sigma-Aldrich, CAS Number
9004-34-6) at a flow rate of 100 µl/min, and washed three
times with 5 ml of washing buffer (50 mM NaOAc, pH 5.2,
50 mM NaCl, 1 mM CaCl2) at a flow rate of 500 µl/min.
Recombinant E2 fusion protein was eluted from the cellulose
matrix with 2 × 5 ml of elution buffer (50 mM Tris-HCl,
pH 8.8, 50 mM NaCl, 1 mM CaCl2, 1% cellobiose). Total
protein and the fractions from flow-through, washing-off, and
elution, as well as the post-elution cellulose beads, were separated
by 10% SDS-PAGE and analyzed by western blotting with
anti-CBD antibody (In-house). The blots were finally stained
with Coomassie Brilliant Blue R-250 (Biosolution, Suwon,
South Korea, Cat. No: BC006).
Size-Exclusion Chromatography and
Native PAGE
For size-exclusion chromatography, the ÄKTA Prime
chromatography system and a HiLoadTM 16/60 Superdex
200 pg (GE Healthcare, Madison, WI, United States) column
were used. The column was washed and equilibrated with
two column volumes (120 ml) of 50 mM Tris-Cl, pH 7.4,
300 mM NaCl, and 0.5 mM EDTA prior to sample injection.
A concentrated protein sample was centrifuged at 18,000 × g
at 4◦C for 20 min with a PURISPIN 17R microcentrifuge
(CRYSTE Separation Technology, United Kingdom),
and the soluble supernatant was carefully injected into
the system with a 1 ml syringe. The chromatography
was performed at 1 ml/min, and 1.5 ml fractions were
collected, with monitoring of protein elution by absorbance
at 280 nm. Fractions corresponding to absorbance peaks
were analyzed by native PAGE on a 9% gel (5.15 ml of
distilled water, 2.9 ml of 30% acrylamide/bis-acrylamide
(37.5:1), 2 ml of 5 × buffer [14.64 g/l imidazole, 41.7 g/l
HEPES], 50 µl of 10% ammonium persulfate, 10 µl of
tetramethylethylenediamine). Ferritin (440 kD), aldolase
(158 kD), and conalbumin (75 kD) (GE Healthcare) were used
as protein molecular-weight standards. The gel was stained with
Coomassie Brilliant Blue R-250.
N-Terminal Amino Acid Sequencing
For N-terminal amino acid sequencing of recombinant
E2 protein, purified protein was transferred from a SDS-
PAGE gel to a polyvinylidene difluoride membrane,
and the transferred protein was analyzed with a
Protein Sequencing System (model 492cLC, Applied
Biosystems, Foster City, CA, United States) at Korea Basic
Science Institute.
Antigenicity of ppE2
Purified ppE2 was serially diluted. Sandwich ELISA was
performed with the VDPro CSFV AG ELISA kit (Median
Diagnostics, Chuncheon, South Korea; Cat. No. ES-CSF-03),
which contains a monoclonal antibody to CSFV E2 protein.
An antibody-coated 96-well plate was incubated at room
temperature for 30 min before use. Dilution solution and
sample (50 µl each) were added to each microplate well.
Positive and negative controls were diluted twofold, and
50 µl of each control was added to a microplate well.
The plate was incubated at 37◦C for 1 h, the reaction
solution was removed, and the plate was washed three
times with 300 µl per well of 1× wash buffer. Then,
100 µl of horseradish-peroxidase (HRP)-conjugated anti-CSFV
antibody was added to each well, incubated at 37◦C for 1 h,
and washed three times with 300 µl of 1× wash buffer.
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate (100 µl) was
added to each well and incubated at room temperature for
10 min, then 50 µl of stop solution was added. Finally, the
absorbance of the solution in each well was read at 405 nm on
an ELISA Reader.
Vaccination of Piglets and Challenge
With CSFV
Piglets were randomly assigned to groups to receive
intramuscular injections with either 50 or 100 µg of ppE2
combined with adjuvant IMS1313, or LOM vaccine. At 20
days after the first injection, a second injection was given
with the same dose as the first. Animals in a control group
were injected with phosphate-buffered saline (PBS). Serum
was collected immediately prior to the first and second
injections, and 4, 7, 10, and 14 days after the second injection,
for examination of the levels of anti-E2 antibodies. The
piglets were challenged with YC11WB, a virulent CSFV
strain, at a virus concentration of 10,000 × LD50, via
intramuscular and intranasal routes. Clinical symptoms
were monitored during the study, and blood samples were
collected at 0, 3, 5, 7, 10, and 13 DPC and used for leukocyte
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counting and antigen detection. Leucopenia was defined as
<9,000 cells/mm3.
ELISA Assay Against CBD
For antigen coating, 100 µl of CBD protein (0.15 ng/µl)
was added to 96-well plates and incubated with CB buffer
(15 mM Na2CO3, 35 mM NaHCO3 and 3 mM NaN3)
at 4◦C for overnight. After eliminating solution, the wells
were washed with PBS-T buffer (PBS buffer + 0.1% Tween
20) for three times. Then, 100 µl of a blocking solution
(3% skim milk and PBS-T buffer) was added and incubated
at 37◦C for 1 h. 1,000- or 2,000-fold diluted serum from
piglets vaccinated with ppE2 or LOM was added to each
microplate well and incubated at 37◦C for 2 h. The wells were
washed with PBS-T and D.W. for three times, respectively.
HRP conjugated anti-pig antibody was diluted by 5,000 and
100 µl of the antibody was added to each well. After
1 h incubation at 37◦C, the wells were washed with PBS-
T and D.W. for three times, respectively. Hundred microliter
of TMB substrate was added to each well and incubated
at room temperature for 10 min. In order to stop the
reaction, 50 µl of 2 M H2SO4 was added and the absorbance
of the solution in each well was read at 405 nm on
an ELISA Reader.
Serological Examination
Aliquots (50 µl) of twofold serially diluted serum were mixed
with 50 µl of 200 × [Median Tissue Culture Infectious
Dose] (TCID50) of CSFV LOM strain in a 96-well plate,
and incubated at 37◦C for 1 h in the presence of 5% CO2.
CPK-16 cells (100 µl of 2 × 105 cells/ml) in Minimum
Essential Medium (MEM) – α Modification (Gibco; Cat.
No. 12571063) containing 10% fetal bovine serum (Biowest;
Cat. No. S1520-500), 1× antibiotic–antimycotic (Gibco;
Cat. No. 15240062), 1× sodium pyruvate (Gibco; Cat. No.
25030081), 1× MEM Non-Essential Amino Acids (Gibco;
Cat. No. 11140050), and 1× L-glutamine (Gibco; Cat. No.
11360070) were added to all wells of the plate. At 72 h
post-inoculation, the cells were fixed with 100 µl of pre-chilled
80% acetone for 7 min at−20◦C. Neutralizing peroxidase-linked
assay was performed with commercial anti-LOM antibody
(Median Diagnostics; Cat. No. 9011) and biotinylated goat
anti-mouse IgG antibody (Vector Lab; Cat. No. BA-9200).
Anti-LOM antibody (100 µl of 200-fold dilution) was added
and incubated for 1 h at 37◦C. Wells were washed with
PBS three times, and 100 µl of 200-fold diluted secondary
antibody was added and incubated for 1 h at 37◦C. After
washing three times with PBS, VECTASTAIN ABC-HRP
Kit (Vector Lab; Cat. No. PK-4000) was added according
to the manufacturer’s instructions and incubated for 1 h at
37◦C. After washing three times with PBS, ImmPACT DAB
Peroxidase (HRP) Substrate (Vector Lab; Cat. No. SK-4100)
was added according to the manufacturer’s instructions.
CSFV-neutralizing antibody titers in serum samples were
expressed as the reciprocal of the highest dilution that caused
50% neutralization.
Detection of CSFV RNA in Blood and
Tissues
To examine the presence of CSFV in infected animals, RNA
was isolated from serum and from tissues (tonsils, heart,
liver, lung, kidney, spleen, mesentery, ileum, caecum, and
brain) with an RNeasy mini kit (Qiagen; Cat No. 74104).
Total RNA was subjected to one-step RT-PCR using VDx
CSFV 5′ NCR RT-PCR (Cat No. NS-CSF-11). Total RNA
(5 µl) and CSFV primer mix (15 µl) were combined and
incubated according to the manufacturer’s instructions. PCR
products were separated on 1.5% agarose gels, and the presence
of the 5′ NCR band was determined after staining with
ethidium bromide.
Single-Dose Vaccination and Challenge
Experiments
Piglets were randomly assigned to five groups and vaccinated
with 100 µg of ppE2 (groups 1–3) or LOM (group 4).
Piglets in the control group (group 5) received PBS only.
ppE2-vaccinated piglets in groups 1, 2, and 3 were kept for
14, 11, and 7 days, respectively, prior to virus challenge.
Piglets vaccinated with LOM were kept for 14 days before
challenge. All piglets were challenged with YC11WB, a virulent
CSFV strain, at a virus concentration of 10,000 × LD50, via
intramuscular and intranasal routes. Clinical symptoms such
as fever and bodyweight were monitored during the study.
Serum was harvested at 3, 7, 10, 14, 17, and 21 DPC and
used for examination of the titers of neutralizing antibodies,
and for WBC counts.
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